The TCLI oncogene on human chromosome 14q32.1 is involved in chromosome translocations [t(14;14)(qll;q32.1) and t(7;14)(q35;q32.1)1 and inversions [inv14(qll;q32.1)] with TCRaIP loci in T-cell leukemias, such as T-prolymphocytic (T-PLL). It is also involved in T-acute and -chronic leukemias arising in cases of ataxia-telangiectasia (AT), an immunodeficiency syndrome. Similar chromosomal rearrangements occur also in the clonally expanded T cells in AT patients before the appearance of the overt leukemia. We have analyzed the expression of TCLI mRNA and protein in peripheral blood lymphocytes (PBLs) from four AT cases and from healthy controls. We found that the TCLI gene was overexpressed in the PBLs of an AT patient with a large clonal T-cell population exhibiting the t (14;14) translocation HE DEVELOPMENT OF human cancer is thought to be a multistep process that entails a progressively more aggressive phenotype through the evolution of cellular subsets with increasing numbers of genetic alterations. The identification of steps that are necessary for the full manifestation of the tumor is currently under study because of its impact on cancer diagnosis and treatment and for our understanding of the malignant process. ' In hematopoietic tumors, cytogenetic alterations such as chromosomal translocations and inversions are quite common. These chromosomal aberrations directly involve genes responsible for malignant transformation,*" but development of leukemias and lymphomas is also a multistep process. It has been shown, for example, that follicular lymphoma (a low-grade malignancy) with BCL2 rearrangement can progress to a more aggressive form of tumor by acquiring a c-but not in the lymphocytes of the other cases. Fluorescence in situ hybridization of the TCLl genomic locus t o lymphocyte metaphases from the AT patient with the T-cell clonal expansion showed that the breakpoint of the t(14; 14) translocation lies within the TCLI locus and is accompanied by an inverted duplication of the distal part of chromosome 14. These data indicate that TCLI is activated in preleukemic clonal cells as a consequence of chromosome translocation involving sequences from the TCR locus at 14ql1. Deregulation of TCLl is the first event in the initiation of malignancy in these types of leukemias and represents a potential tool for clinical evaluation. 0 1995 b y The American Society of Hematology.
MYC gene r e a~a n g e m e n t~.~; another example is the clinical transition from chronic to acute phase in chronic myelogenous leukemia, in which p53 mutations and deletions are observed in 20% to 30% of the cases of blastic crisis. 6 An excellent model for studying tumor progression is represented by T-cell leukemias arising in patients with ataxia-telangiectasia (AT), an immunodeficiency syndrome associated with genomic instability, deficient DNA repair, cerebellar ataxia, and oculocutaneous telangiectasias. These patients are prone to cancer (IO%), especially of the hematopoietic lineage, with a 70-to 250-fold increase in the probability of developing lymphocytic leukemia and lymphoma, particularly in childhood.' In contrast to the general popuiation, in which B-cell leukemias are predominant, leukemias of T-cell phenotype are particularly frequent in the AT population. In these patients, the presence of clonal T-cell expansions has been observed before the onset of full-blown leukemia (reviewed by Kirshx). These expansions are of two types. The first type of expansions is characterized by translocations and inversions [t(7;7)(p15;q35), inv 7(p15;q35), t(7; 14)(q35;ql l), and t(7; 14)(p15;ql l)] that usually involve rearrangements among T-cell receptor genes" and are not associated with neoplasia. The second type of expansions, which is observed in 7% of 10% of all AT cases,' involves the clonal expansion of cells carrying either the t(14; 14)(ql1;32.1) translocation or inv 14(ql I;q32.l)inversion, or more rarely t(X; 14)(q28;qll). In these cases, cells tend to expand in the peripheral blood with time until they represent 90% to 100% of all circulating lymphocytes and invariably progress to a frank leukemia.'0-'2 Chromosomal translocations in the latter cases involve on one side the TCRa locus on chromosome 14ql1 and, on the other side, either the TCLl gene on 14q32. 1I3 
MATERIALS AND METHODS
Patient samples and pur8cation of T cells. Lymphocytes from four patients with AT and a healthy donor were analyzed in this study. AT94-1 is a 16-year-old girl with classical AT. The first karyotypic analysis of her lymphocytes was performed in 1986 and showed 4% clonal cells carrying a t(14; 14) (91 l;q32.1). This abnormality increased to 60% and has remained stable at this frequency in the last two semiannual observations."" The white blood cell count was 6,22O/mL, with lymphocytes ranging around 14.4%. The phenotype of her PBLs at the time of the last observation was the following: CD45+CD3+ (65%). CD45+CD20f (1 l%), TCRdP (61%). TCRyI6 (3%), CD4+ (49%), CD8' (17%).
T cells from AT94-1 and from a normal donor were enriched by adhering B cells and monocytes to a nylon-wool column at 37°C for 60 minutes and T-enriched cells were collected in the eluted fraction. After purification, T cells from normal control and AT94-1 represented approximately 778, with the remaining cells being CD3-CD56' (natural killer cells) and less than 1% being CD19+ (B cells).
The other three patients were classical AT cases without cytogenetically evident clonal expansions.
Cytogenetics and fluorescence in situ hybridization (FISH). Chromosome preparations were obtained using standard methods from 72-hour lymphocyte phytohemagglutinin-stimulated cultures of AT patients. Analysis of spontaneous chromosome rearrangements was performed on at least 30 G-banded metaphases.
For FISH analysis, the cosmid clones pPLC-1 and pPLC-4 were isolated by screening a human placental genomic library using probes B0.9 and pE/S." The pPLC-4 cosmid contains a genomic fragment corresponding to the region from pE/S to the region 40 kb centromeric to pE/S (Fig ID) . The TCLl gene, and pPLC-1 cosmid are located about 120 and 250 kb centromeric to the end of the pPLC-4 cosmid, respectively.'* For in situ hybridization, pPLC-1 or pPLC-4 was labeled with biotin-16-dUTP or digoxigenin-l I-dUTP, respectively, using a nick-translation kit (Bethesda Research Laboratories, Gaithersburg, MD). The hybridization mixture contained 200 ng each of both labeled probes, pPLC-1 and pPLC-4, as well as IO pg of sonicated salmon sperm DNA, 10 pg of Escherichia coli tRNA, and 350 ng of human Cot-l DNA (Bethesda Research Laboratory) in 10 pL of 50% formamide, 50 mmol/L phosphate, 10% dextran sulfate, 2X SSC, pH 7.0. Before hybridization, the mixture was denatured at 75°C for 5 minutes, quickly chilled, and incubated at 37°C for 30 minutes to compete for repetitive sequences in the probe. After overnight hybridization, the slides were washed for 20 minutes in 50% formamide, 2 x SSC, pH 7.0, at 37"C, followed by two 15-minute washes in 2X SSC, and finally rinsed in 4 x SSC at room temperature. Fluorescein isothiocyanate (FITC)-conjugated avidin and antidigoxigenin tagged with rhodamine (Boehringer Mannheim, Mannheim, Germany) were used for the detection of biotinylated pPLC-1 and digoxigenin-labeled pPLC-4. The chromosomes were counter-stained with 0.1 pg/mL of Hoechst 33258 DNA dye.
RNA extraction. A total of 7 to 10 mL of venous blood was obtained by standard venipuncture techniques using heparinazed tubes, mixed with an equal volume of RPMI medium, and then layered over 8 mL of Ficoll (Pharmacia, Uppsala, Sweden) in a 50-mL polystyrene tube.The gradient was centrifuged at 800g for 20 minutes. The lymphomonocyte layer was collected and washed twice with RPMI medium and then sedimented at 300g for 15 minutes. The supernatant was discarded and the pellet containing nucleated cells was used for RNA extraction using the RNAzol B method as described by the manufacturer (Tel-Test, Inc, Friendswood, TX).
Semiquantitave reverse transcriptase-polymerase chain reaction (RT-PCR). cDNA was made from total RNA using random primer oligonucleotides. Approximately 0.5 pg of RNA in a final volume of 35 pL was first denatured at 80°C for 5 minutes and then cooled on ice. First-strand DNA synthesis was performed by adding 1 pL of Superscript Reverse Transcriptase (Stratagene, La Jolla, CA), 100 mmol/L ditiothreitol (DTT), IOX RT buffer, 40 pmoVL of random primers, 40 pmoVL dRPN6 (Boheringer Mannheim), 10 mmoVL of dNTP, and 36 U of RNAse block to a final volume of 50 pL.
For monitoring the cDNA synthesis, 5 pL of this reaction was removed at the beginning of the synthesis and 5 pCi of a 32Phospho-NS dATP (800 mCi/mL) was added to the reaction. The two reactions (radiolabeled and not radiolabeled) were left at 37°C for 1 hour; the two cDNAs were then boiled for 5 minutes or kept on ice or at -70°C for further use. The radioactive fraction was purified through Sephadex Nick Spin Columns according to the manufacturer's instructions (Pharmacia) and then counted on a p scintillation counter (Packard, Downers Grove, L) to evaluate the cDNA synthesis. The same amount of nonradioactive cDNAs was then used for PCR amplification. All the cDNA samples in Fig 2 were synthetized and used for PCR amplification in the same set of experiments to minimize the variations.
The primers used for amplification of a 306-bp product of the TCLl transcript by PCR were TCL1-U1 (S'AGGCCTATGACCCC-CACC3'), corresponding to the + strand from bp 232-249, and TCLI-R2 (5'CATTCCTCCCAGACCCCA3'), corresponding to the "strand from bp 51 1-529 of the TCLI.
Primers specific for amplification of a 154-bp product of the housekeeping @actin gene were A1 (STCATCACCATTGGCAAT-GAG3') and A2 (5'GTGTTGGCGTACAGGT3'). PCR and amplification were performed under the following conditions: denaturing for 1 minute at 94"C, annealing for 1 minute at 6 0 T , and elongation for 1 minute at 72°C for 25 cycles (TCL1) or 15 cycles (&actin).
Immunostaining. Immunohistochemistry was performed on cytospins of T-cell-enriched PBLs. The slides were fixed in 100% acetone for 5 minutes, dried, postfixed in 4% paraformaldehyde for IO minutes, washed in phosphate-buffered saline (PBS), and immunostained with optimal dilutions of anti-TCLI polyclonal rabbit antiserum and mouse monoclonal anti-CD7, -CD19, and -CD68. Cytospins were preincubated with goat antiserum or rabbit serum and sequentially incubated with primary antibodies, goat antirabbit IgG, rabbit antimouse IgG, rabbit antiperoxidase (PAP), or mouse peroxidase antiperoxidase. Each incubation step lasted 30 minutes and was followed by 10 minutes of washing in PBS. The slides were then incubated with 0.03% Hz02 and 0.06% 3, 3'-diaminobenzidine for 2 to 5 minutes, washed in tap water, and counterstained with hematoxylin. The number of positive cells was determined by light microscopy at 400X magnification in five fields and expressed as the percentage of positive cells. No evident clonal populations with rearrangements at 14q32 were observed in lymphocytes of the other AT cases. To determine whether in AT 94-1 lymphocytes the DNA joined at the t(14; 14) breakpoint involved the TCLl locus, we conducted FISH analysis using probes close to the TCLl breakpoint. Two cosmid clones, pPLC-I , localized about I20 kb centromeric to the TCLl gene, and pPLC-4, localized about 250 kb telomeric to the TCLl gene, were used (Fig  l) . The biotinylated cosmid pPLC-I and digoxigenin-labeled pPLC-4 were simultaneously hybridized to AT lymphocyte metaphases. The signals from pPLC-I and pPLC-4 were visualized using FITC-conjugated streptavidin-and rhodamine-conjugated antidigoxigenin antibody, respectively.
RESULTS

Cytogenetic analysis of the t (14;14) breakpoint. The cytogenetic analysis by chromosome banding performed on
The results of in situ hybridization experiments are shown in Fig 1. The hybridization of the pPLC-I probe showed the presence of two peaks of hybridization on the t( 14; 14) chromosome [one located slightly centromeric to the translocation breakpoint and the other located on the tip of long arm of the t(14; 14); Fig IA] , whereas the signal of pPLC-4 showed three peaks of hybridization (one slightly centromeric to the breakpoint, one at the breakpoint site, and the third at the tip of the der 14; Fig IB) .
These results show that this rearrengement involves the TCLI locus splitting the two probes, pPLC-I and pPLC4, at the breakpoint site; furthermore, the orientation of the pPLCl and pPLC4 at the junction is inverted with respect to the germline position (Fig IE) , because pPLC-4 localized telomeric to both TCLl and pPLC-I. This result indicates that an inversion duplication event had also occurred in this chromosome.
As we have already desribed,Ix this translocation, accompanied by an inverted duplication, will behave, in terms of juxtaposition of TCR elements ( 1 4 q l l ) to the TCLl gene, in a manner similar to that of the inv( 14)(ql l;q32.1) chromosome inversions. This inverted duplication event seems to be quite frequent on T-cell preleukemic and malignant clones, with a t( 14; 14) translocation in AT and could result from chromosomal instabilty underlying the primary defect of AT.
TCLl expression in AT and normal Iyrnphoqtes. Because the 14q32.1 breakpoint of case AT94-1 was, as expected, in the TCLl locus, we investigated TCLl expression in cells from this case to determine whether the expression was altered from that seen in normal PBLs. For this purpose, we performed semiquantitative PCR amplification of reverse-transcribed mRNAs derived from lymphocytes of AT 94-1, from three other AT cases without apparent clonal cells harboring a t( 14; 14) translocation, and from the Daudi cell line that expresses high levels of TCLl protein. I3 Reverse transcripts derived from RNAs of these cells were normalized, as described in the Materials and Methods. and were amplified by PCR with TCLl and &actin primers.
As shown in Fig 2, the level of TCLl expression in AT 94-1 cells is much higher that the level of expression of TCLl mRNA observed in the other three cases of AT. cDNAs derived from three healthy donors expressed levels of TCLl comparable to those of the latter three AT cases (data not shown). The level of p-actin was also used for further control. &Actin was amplified from the same amount of cDNA template used for TCLl amplification independently for IO, 15, or 20 cycles to determine whether the amplification is in the linear phase, because the level of amplification of this gene reaches a plateau effect under the conditions used for TCL-l. Results obtained at 15 cycles (linear phase) for the housekeeping &actin gene also confirmed the data of amplification observed for TCLl primers (Fig 2) .
We then conducted immunostaining of T-cell-enriched PBLs from AT94-1 and from a normal donor using a rabbit polyclonal antiserum raised against TCLl recombinant protein." After enrichment on a nylon-wool column, 77% of the cells were of T-cell origin, as demonstrated by staining with an anti-CD7 monoclonal antibody (data not shown).
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Cytospins of the two samples were then stained with anti-TCL1 antiserum; 27% of the AT94-1 (Fig 3A) cells showed a strong cytoplasmic signal for the TCLl protein, whereas less than 1 % of the T-cell-enriched population from the normal donor ( Fig  3B) showed positive signals. We also analyzed cytospins of unfractioned PBLs from another AT patient; only 0.8% of the cells stained positive (data not shown).
These (14) chromosome translocations or inversions and expand over time to represent up to 100% of the T-cell population. These preleukemic cells consistently progress to a overt leukemic stage that usually resembles the one observed in T-PLL. '7.27 Taking advantage of the recent molecular cloning of the TCLl gene, we have shown that TCLl is overexpressed at the RNA and protein level in one case of AT bearing 60% of clonal T cells with a t(14; 14)(qll.q32.1) with the breakpoint in the TCLl locus compared with other AT cases and normal healthy individuals without apparent clonal populations of T cells. These results indicate a pivotal role for TCLl in the initiation of malignant transformation of these T-cell leukemias.
As a consequence of the translocation event, regulatory elements, such as enhancers of the TCRa gene, move in proximity of the TCLl gene, probably dysregulating its expression. It seems that TCLl deregulation confers a proliferative advantage to T cells; whether this is due to an increase in cell survival or to a mitogenic stimulus is currently under investigation and will remain unknown until the function of this gene is ascertained. However, these results suggest that the TCLl product acts as an inducer of T-cell expansion. This situation can last for many years, and additional changes may be required for a full malignant transformation. This last situation is apparent in vivo in T-PLLs in which the t( 14; 14)translocation or the inv (14) inversions are involved in 75% of the cases and in which other cytogenetically abnormalities, such as is0 8q or is0 20, are also consistently present.I6 These other rearrangements or other genetic events could play a secondary role in tumor progression.
Shemngton et all2 have recently studied similar cases of clonal expansion in two cases carrying a t(14; 14) and a t(X; 14) translocation. By means of densitometric studies on serial samples using probes detecting a rearrangement band at the TCLl locus and the TCR p-locus, they have shown that cells containing the translocation are oligoclonal with respect to TCRP in the preleukemic stage and p-clonality was established at the time of the leukemia. In the present report, we have not analyzed this aspect, but the presence of several other small clones at cytogenetic analysis could suggest the possibility of different oligoclonal populations within the t( 14; 14) clone, indicating, in agreement with these investigators, that rearrangements at the TCLl locus can occur at a very early stage during ontogeny of the immune system. This hypothesis is also substained by the presence, near the breakpoint of molecularly cloned ~ases,2.*.".'~ of elements such as heptamer-nonamer sequences and of Nregion, indicating that such events may take place during VDJ rearrengement of T-cell receptor genes.
It has been reported in the literature that at least 10% of these patients will, over time, develop a clonal T-cell population in their peripheral blood that can comprise 100% 2363 of the peripheral T-cell metaphases karyotypically analyzed. Availability of antibodies and molecular diagnostics based on TCLl RT-PCR could help to detect and to monitor these leukemias from their early stages.
These data also raise the possibility of alternative approaches for treating these early stages in AT patients that, as is widely known, are particularly difficult to treat using conventional cytostatic therapy. Innovative therapies aimed at the TCLl gene or at its product may result in the purging of leukemic cells.
